SCHEMBL167218

SCHEMBL167218

[2H]C([2H])(c1ccnc(N)c1)n1ccc2c(NC(=O)Nc3cccc(Br)c3)cccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.42
PARP1 P09874 2/20 0.42
BUB1 O43683 1/20 0.41
PTGER3 P43115 1/20 0.41
EPHB4 P54760 2/20 0.41
CDK8 P49336 2/20 0.40
KDR P35968 3/20 0.38
NTRK1 P04629 2/20 0.38
NTRK2 Q16620 2/20 0.38
FLT1 P17948 2/20 0.38
STING1 Q86WV6 1/20 0.38
PLK4 O00444 1/20 0.38
AURKA O14965 1/20 0.38
ROCK2 O75116 1/20 0.38
RPS6KA5 O75582 1/20 0.38
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38
INSR P06213 1/20 0.38
LCK P06239 1/20 0.38
CSF1R P07333 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL168209 0.92 KDR (0.37) CDK8KDRFLT1STING1ROCK2
SCHEMBL168670 0.91 MAPT (0.40) TRPV1BUB1KDRROCK2RET
SCHEMBL166695 0.89 MEN1 (0.46) TRPV1PTGER3EPHB4CDK8KDR
SCHEMBL169174 0.89 KDR (0.43) TRPV1PTGER3EPHB4CDK8KDR
SCHEMBL166850 0.89 KMT2A (0.42) TRPV1PTGER3CDK8KDRNTRK1
SCHEMBL167600 0.88 EPHB4 (0.39) TRPV1EPHB4KITROCK1MAPT
SCHEMBL166951 0.88 FGFR1 (0.36) TRPV1BUB1EPHB4KDRFLT1
SCHEMBL167806 0.87 TRPV1 (0.48) TRPV1PTGER3EPHB4CDK8KDR
SCHEMBL164668 0.87 ALDH1A1 (0.44) EPHB4KDRFLT1ROCK2KIT
SCHEMBL169268 0.87 PTGER3 (0.48) TRPV1PTGER3CDK8ROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2013-06-27 US claimed
EP-2611806-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS Ascepion Pharmaceuticals, Inc. (CN) 2013-07-10 EP disclosed
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2013-06-27 US disclosed
WO-2012028106-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK2, CDK1, CDK3 TRPV1 4297/4885PARP1 2096/4885BUB1 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.